Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320878 | PMC |
| http://dx.doi.org/10.1155/2015/524507 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Literature review of the clinical features of sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DIHS).
Front Pharmacol
December 2024
Department of Clinical Pharmacy, Xiangtan Central Hospital (The Affiliated Hospital of Hunan University), Xiangtan, China.
Background: Sulfasalazine (SSZ) is commonly prescribed for the treatment of ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis. However, it can also trigger a severe drug reaction known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) or Drug-Induced Hypersensitivity Syndrome (DIHS). This article aims to analyze the clinical characteristics of DRESS/DIHS induced by SSZ and provide evidence for clinical diagnosis, treatment, and prevention.
View Article and Find Full Text PDFImmunosuppressants in dermatology on vaccine immunogenicity: a prospective cohort study of pemphigus patients in the pandemic.
Front Immunol
December 2024
Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Keelung, Taiwan.
Introduction: Both cellular and humoral responses are important for vaccine protection, but recommendations on immunosuppressants in dermatology are largely based on pre-pandemic experiences. This study aimed to investigate the impacts of immunosuppressants on humoral and cellular immunogenicity to COVID-19 vaccinations in pemphigus patients.
Methods: SARS-CoV-2-naïve pemphigus patients and age-, and sex-matched healthy controls were recruited from multiple tertiary medical centers during 2021-2023.
Rituximab-Induced Hypersensitivity Pneumonitis in Multiple Sclerosis: A Rare Phenomenon.
Ann Indian Acad Neurol
December 2024
Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Urticarial vasculitis.
Curr Opin Rheumatol
January 2025
Marmara University School of Medicine, Department of Dermatology, Istanbul, Türkiye.
Article Synopsis
- Urticarial vasculitis (UV) is a rare condition that can range from mild skin issues to serious systemic problems, and recent research focuses on its causes, diagnosis, and treatment options.
- New triggers for UV associated with SARS-CoV-2 and COVID-19 vaccines have been noted, along with a new clinical-dermoscopic method for diagnosis that reduces reliance on skin biopsies.
- Treatments such as antihistamines, corticosteroids, and rituximab show promise for success and long-lasting remission, while epidemiological studies show good survival rates but highlight certain severe health issues that can increase mortality.
Retrospective analysis of rapid drug desensitization with biologic agents: A single center experience.
Clin Transl Allergy
October 2024
Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey.
Background: Following the increased use of biological agents, a subset of patients experiences hypersensitivity reaction (HSR). We reported our experience with rapid drug desensitization (RDD) to nine biologics (rituximab, infliximab, cetuximab, trastuzumab, pertuzumab, nivolumab, brentuximab, tocilizumab and filgrastim) and identified risk factors for breakthrough reactions (BTRs).
Method: This was a retrospective review (2013-2022) of patients with immediate HSRs to biological agents.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!